Xyphos is developing treatments for relapsed hematological malignancies and solid tumors using our flexible and controllable CAR-T cell therapy platform called ACCEL™ (Advanced Cellular Control through Engineered Ligands). ACCEL enables precise control of activity and targeting of our universal CAR-T cell, termed convertibleCAR-T™, using any tumor-specific full antibody and can add critical functionality to convertibleCAR-T cells.